Tigliya Tablets 90 mg (Ticagrelor)

Adult dose

Do not use this medicine in combination with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). Acute coronary syndrome: Administer an initial dose of 180mg, followed by 90mg twice daily. Treatment is recommended for 12 months unless discontinuation of this medicine is clinically necessary. Patients taking this medicine should also take a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients with a history of myocardial infarction (occurring at least 1 year previously) and at high risk of thrombotic cardiovascular events: Administer 60mg twice daily. Patients taking this medicine should also take a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients who took 90mg of this medicine or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with 60mg of this medicine. Treatment with this medicine may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuation of a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). The safety and efficacy of this medicine were evaluated at 3 years of follow-up. Patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60mg twice daily. Patients taking this medicine should also take a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. For patients with acute coronary syndrome, refer to the corresponding dosage and administration. Data on the safety and efficacy of this medicine for treatment exceeding 3 years are limited. Patients with acute ischemic stroke or high-risk transient ischemic attack: Administer an initial dose of 180mg, followed by 90mg twice daily for 30 days. Patients taking this medicine should also take a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. An initial loading dose of aspirin (300-325mg) is recommended for patients with acute ischemic stroke or high-risk transient ischemic attack. This medicine is administered orally and may be taken with or without food. For patients who have difficulty swallowing tablets, crush this medicine into a fine powder, disperse it in half a glass of water, and drink it. Rinse the glass with another half glass of water and drink it. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the nasogastric tube with water after administration. When switching from another antiplatelet agent to this medicine, start this medicine 24 hours after the last dose of the previous medicine. If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. No dose adjustment is necessary in patients with renal impairment. No dose adjustment is necessary in patients with mild hepatic impairment. This medicine has not been studied in patients with severe hepatic impairment, and experience with its use in patients with moderate hepatic impairment is limited.

Child dose

The safety and efficacy of this medicine in pediatric patients under 18 years of age have not been established (see “Other” section).

This medicine inhibits platelet aggregation to prevent thrombus formation and is used in the prevention and treatment of cardiovascular diseases. It should not be used by patients who have a history of bleeding or intracranial hemorrhage due to the risk of bleeding. Patients scheduled for surgery should discontinue this medication at least 5 days prior to the procedure, and should inform medical personnel immediately if any signs of bleeding appear. Patients at high risk of bleeding or those taking other medications that may increase bleeding should use this medication with caution. This medication may cause side effects such as bradycardia or respiratory distress, hence caution is necessary for patients with related symptoms. Women who are pregnant or breastfeeding should avoid using this medication, and women of childbearing age should use appropriate contraception to prevent pregnancy. It is not recommended for children under 18 years of age as safety and efficacy have not been established. This medication may affect liver and kidney function, so regular testing is needed, especially for the elderly or those with severe renal impairment. There may be interactions with other medications, so it is essential to inform medical personnel of any medications currently being taken. In case of overdose, excessive suppression of blood coagulation may increase the risk of bleeding, so it is crucial to adhere strictly to the prescribed dosage and seek immediate medical attention if any abnormal symptoms occur. Dizziness or confusion may occur while taking this medication; therefore, caution is advised when driving or operating machinery. Keep out of reach of children, and store in the original container to maintain quality.

• Hemorrhage
• hypotension
• confusion
• dizziness
• syncope
• headache
• intracranial hemorrhage
• ocular hemorrhage
• vertigo
• ear hemorrhage

This medication should be stored in a tightly closed container to protect it from air and moisture, and it is safe to store at room temperature between 1 to 30 degrees Celsius.

Appearance

Yellow, round, biconvex, film-coated tablet

Package unit

60 tablets/PTP (10 tablets/PTP x 6)